Patents Assigned to Ribozyme Pharmaceuticals, Inc. and Chiron.
  • Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
    Publication number: 20040077565
    Abstract: The present invention relates to nucleic acid molecules such as ribozymes, DNAzymes, and antisense which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor, such as flt-1 and KDR. Nucleic acid molecules and methods for the inhibition of angiogenesis and treatment of cancer and ocular diseases are provided, optionally in conjunction with other therapeutic agents.
    Type: Application
    Filed: May 3, 2002
    Publication date: April 22, 2004
    Applicant: Ribozyme Pharmaceuticals, Inc. and Chiron.
    Inventors: Pamela Pavco, James McSwiggen, Dan Stinchcomb, Jaime Escobedo